Toronto, Ontario--(Newsfile Corp. - February 10, 2026) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the ...
Bitcoin lost roughly 50 percent as tight liquidity and macro shocks overwhelmed bullish narratives. Higher interest rates, ETF outflows, and rising Nasdaq correlation weakened Bitcoin’s risk appeal.
U.S. grid regulators warned that North America’s electric power system is not expanding fast enough to meet rising demand, meaning that several regions are at heightened risk of shortages over the ...
A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the company’s bread-and-butter Xifaxan—a ...
Hosted on MSN
Insmed halts CRSsNP program after Phase 2b failure
The latest announcement is out from Insmed ( (INSM)). On December 17, 2025, Insmed announced the Phase 2b BiRCh study of brensocatib for chronic rhinosinusitis without nasal polyps (CRSsNP) did not ...
argenx SE retains a Hold rating due to valuation constraints and pipeline setbacks, despite strong commercial execution with VYVGART. Recent termination of TED and lupus nephritis programs narrows ...
Two Sarepta Therapeutics drugs for treating different genetic subsets of patients with Duchenne muscular dystrophy failed the confirmatory study required of their accelerated FDA approvals. Sarepta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results